Tyra Biosciences, Inc. (NASDAQ:TYRA – Free Report) – Research analysts at HC Wainwright lowered their Q2 2026 EPS estimates for shares of Tyra Biosciences in a research report issued to clients and investors on Thursday, May 14th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($0.69) per share for the quarter, down from their previous estimate of ($0.65). HC Wainwright has a “Buy” rating and a $45.00 price target on the stock. The consensus estimate for Tyra Biosciences’ current full-year earnings is ($2.57) per share. HC Wainwright also issued estimates for Tyra Biosciences’ Q3 2026 earnings at ($0.70) EPS, Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($2.74) EPS, Q1 2027 earnings at ($0.74) EPS, Q2 2027 earnings at ($0.77) EPS and FY2027 earnings at ($3.09) EPS.
A number of other research firms have also recently commented on TYRA. Piper Sandler increased their target price on shares of Tyra Biosciences from $42.00 to $56.00 and gave the company an “overweight” rating in a research report on Friday, March 20th. William Blair initiated coverage on shares of Tyra Biosciences in a research report on Tuesday, February 10th. They set an “outperform” rating for the company. Guggenheim initiated coverage on shares of Tyra Biosciences in a research report on Tuesday, April 14th. They set a “buy” rating and a $54.00 target price for the company. Cantor Fitzgerald started coverage on shares of Tyra Biosciences in a research report on Tuesday, February 24th. They set an “overweight” rating for the company. Finally, Wedbush upped their price target on shares of Tyra Biosciences from $37.00 to $53.00 and gave the company an “outperform” rating in a research note on Friday, February 13th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Tyra Biosciences has an average rating of “Moderate Buy” and an average target price of $46.50.
Tyra Biosciences Stock Performance
Shares of TYRA opened at $35.66 on Tuesday. The company has a 50 day moving average price of $36.19 and a 200-day moving average price of $29.23. Tyra Biosciences has a fifty-two week low of $8.75 and a fifty-two week high of $40.65. The stock has a market capitalization of $2.12 billion, a PE ratio of -16.36 and a beta of 0.79.
Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.04).
Insider Buying and Selling at Tyra Biosciences
In other news, Director Gilla Kaplan sold 14,295 shares of the firm’s stock in a transaction dated Wednesday, March 25th. The shares were sold at an average price of $36.97, for a total value of $528,486.15. Following the transaction, the director directly owned 28,231 shares of the company’s stock, valued at approximately $1,043,700.07. This trade represents a 33.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 12.50% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the business. Hilton Head Capital Partners LLC acquired a new position in shares of Tyra Biosciences in the first quarter valued at approximately $30,000. Caitong International Asset Management Co. Ltd purchased a new position in Tyra Biosciences in the fourth quarter worth approximately $51,000. Chung Wu Investment Group LLC purchased a new position in Tyra Biosciences in the fourth quarter worth approximately $53,000. Federated Hermes Inc. lifted its stake in Tyra Biosciences by 586.3% in the third quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock worth $30,000 after acquiring an additional 1,841 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Tyra Biosciences by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock worth $68,000 after buying an additional 534 shares during the last quarter. Institutional investors and hedge funds own 84.14% of the company’s stock.
About Tyra Biosciences
Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.
The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.
Read More
- Five stocks we like better than Tyra Biosciences
- Why Trump’s Amazon Stock Sale May Not Matter at All
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
